Deverra Therapeutics, Inc. — Form C/A (Regulation Crowdfunding)
Deverra Therapeutics, Inc. of Seattle, WA filed a Form C/A (Regulation Crowdfunding) with the SEC on 2024-04-26. Target raise $15K, up to $1.2M. Offered through StartEngine Capital, LLC.
Offering
- Filed: 2024-04-26
- Form: C/A
- Accession: 0001665160-24-000559
- Target amount: $15K
- Maximum amount: $1.2M
- Security type: Common Stock
- Securities offered: 7,177
- Price: $2.0900
- Deadline: 2024-07-01
- Funding portal / intermediary: StartEngine Capital, LLC
- Intermediary file number: 007-00007
Issuer
- CIK: 0001822782
- Website: https://www.deverratx.com/
- Legal status: Corporation
- Organized in: DE
- Incorporated: 2020-09-11
- Address: 1600 Fairview Ave E STE 300, Seattle, WA, 98102
- Employees: 12
Financials (as filed)
- Total assets (most recent): $7.2M
- Cash (most recent): $265K
- Revenue (most recent): $1.7M
- Net income (most recent): $1.7M
- Net income (prior): $-6.9M
- Short-term debt: $7.2M
People (5)
| Name | Role | Location |
|---|
| Andrew Albert Kucharchuk | Interim CFO | South San Francisco, CA |
| Colleen Delaney | Scientific Founder and Chief Scientific Officer, EVP of RandD, Director | Wexford, PA |
| Colleen Delaney | Scientific Founder and Chief Scientific Officer, EVP of R&D, Director | Wexford, PA |
| Michael Yurkowsky | CEO | Seattle, WA |
| Michael Yurkowsky | CEO, Director and Chairman | Seattle, WA |
Reg CF filing history (7)
More